<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432286</url>
  </required_header>
  <id_info>
    <org_study_id>16352</org_study_id>
    <secondary_id>I5Q-MC-CGAS</secondary_id>
    <secondary_id>2017-004351-23</secondary_id>
    <nct_id>NCT03432286</nct_id>
  </id_info>
  <brief_title>A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine</brief_title>
  <acronym>REBUILD-1</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in&#xD;
      participants 6 to 17 years of age for the preventive treatment of episodic migraine. The&#xD;
      primary objective is to demonstrate the superiority of galcanezumab versus placebo in the&#xD;
      reduction of monthly migraine headache days across the 3-month double-blind treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has two parts which enroll separately from each other such that participants may&#xD;
      choose to participate in either but not both: the main study and a study addendum.&#xD;
&#xD;
        -  The main study includes a 3-month, randomized, double-blind treatment period in which&#xD;
           participants receive either galcanezumab or placebo, followed by a 9-month open-label&#xD;
           extension in which all participants receive galcanezumab.&#xD;
&#xD;
        -  The study addendum is a stand-alone study of galcanezumab pharmacokinetics and safety in&#xD;
           a group of participants separate from those in the main study. The study addendum&#xD;
           includes a 5-month evaluation period after a single injection of galcanezumab, followed&#xD;
           by a 9-month open-label extension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">January 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headache days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Reduction from Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of participants with reduction from baseline ≥50%, ≥75% and 100% in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headache Days with Nausea and/or Vomiting</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headache days with nausea and/or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headache Days with Photophobia and Phonophobia</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headache days with photophobia and phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headaches with Prodromal Symptoms</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headaches with prodromal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Migraine Headache Days on which Acute Headache Medication is Taken</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of migraine headache days on which acute headache medication is taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression-Improvement (PGI-I) Rating</measure>
    <time_frame>Month 1 to Month 3</time_frame>
    <description>PGI-I rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Severity of Remaining Migraine Headaches per Month</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the severity of remaining migraine headaches per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Pediatric Quality of Life Inventory (PedsQL) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from Baseline on the PedsQL total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Pediatric Migraine Disability Assessment Test (PedMIDAS) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline on the PedMIDAS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the C-SSRS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>PK: Serum concentration of galcanezumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Plasma concentration of CGRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Percentage of participants developing anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Initiate Migraine Prevention Medication in the Post-Treatment Follow-Up Phase</measure>
    <time_frame>16 Months</time_frame>
    <description>Percentage of participants who initiate migraine prevention medication in the post-treatment follow-up phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">325</enrollment>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered by SQ injection.&#xD;
Participants may be eligible for optional open-label extension at the end of the double-blind period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by SQ injection.&#xD;
Participants may be eligible for optional open-label extension at the end of the double-blind period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of migraine with or without aura as defined by the IHS ICHD-3&#xD;
             guidelines (1.1 or 1.2 according to ICHD-3 [2018]), with a history of migraine&#xD;
             headaches of at least 6 months prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are taking, or are expected to take, therapeutic antibodies during&#xD;
             the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.).&#xD;
             Prior use of therapeutic antibodies, other than antibodies to calcitonin gene-related&#xD;
             peptide (CGRP) or its receptor, is allowed if that use was more than 12 months prior&#xD;
             to baseline.&#xD;
&#xD;
          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic&#xD;
             proteins, or to galcanezumab or its excipients.&#xD;
&#xD;
          -  Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor&#xD;
             antibody, including those who have previously completed or withdrawn from this study&#xD;
             or any other study investigating a CGRP antibody.&#xD;
&#xD;
          -  History of persistent daily headache, cluster headache or migraine subtypes including&#xD;
             hemiplegic (sporadic or familial) migraine and migraine with brainstem aura&#xD;
             (previously basilar-type migraine) as defined by IHS ICHD-3.&#xD;
&#xD;
          -  History of significant head or neck injury within 6 months prior to screening; or&#xD;
             traumatic head injury at any time that is associated with significant change in the&#xD;
             quality or frequency of their headaches, including new onset of migraine following&#xD;
             traumatic head injury.&#xD;
&#xD;
          -  Participants with a known history of intracranial tumors or developmental&#xD;
             malformations including Chiari malformations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rehabilitation &amp; Neurological Services LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>358054046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>256-885-9708</phone>
    </contact>
    <investigator>
      <last_name>Belinda A. Savage-Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Neurology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-265-6500</phone>
    </contact>
    <investigator>
      <last_name>Stephen Flitman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute at Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Little</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>520-795-0229</phone>
    </contact>
    <investigator>
      <last_name>Dinesh Talwar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806-1737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>562-933-1713</phone>
    </contact>
    <investigator>
      <last_name>Jasmin Dao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange County Research Institute - Ontario</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(909) 395-9788</phone>
    </contact>
    <investigator>
      <last_name>Rosario Badar Retino MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center For Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6195212830</phone>
    </contact>
    <investigator>
      <last_name>Todd Tyler Simmons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>720-777-5099</phone>
    </contact>
    <investigator>
      <last_name>Marcy Yonker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9042815757</phone>
    </contact>
    <investigator>
      <last_name>Nandita Joshi Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alphab Global Research</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-626-5551</phone>
    </contact>
    <investigator>
      <last_name>Laszlo J Mate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-243-8555</phone>
    </contact>
    <investigator>
      <last_name>Danielle Horn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ezy Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>786-483-8162</phone>
    </contact>
    <investigator>
      <last_name>Desiree Ortiz-Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare, LLC</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4076542724</phone>
    </contact>
    <investigator>
      <last_name>Kelly Nanette Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Inst of Florida-Clinical Neuroscience Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-425-5100</phone>
    </contact>
    <investigator>
      <last_name>Linda S Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-941-3330</phone>
    </contact>
    <investigator>
      <last_name>Akiva Daum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-4799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-974-0979</phone>
    </contact>
    <investigator>
      <last_name>Kavita Kalidas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>813-264-2155</phone>
    </contact>
    <investigator>
      <last_name>Tanya R Bogle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>2086850600</phone>
    </contact>
    <investigator>
      <last_name>Brock Aaron McConnehey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research LLC</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>2083778653</phone>
    </contact>
    <investigator>
      <last_name>Mark Alan Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMITA Health - Alexian Brothers Neurosciences Institute Clinical Research</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>847-593-8553</phone>
    </contact>
    <investigator>
      <last_name>Abdul Mazin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky College of Medicine</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>859-323-5661</phone>
    </contact>
    <investigator>
      <last_name>Sharoon Qaiser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-602-1440</phone>
    </contact>
    <investigator>
      <last_name>Sarah Herts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-202-6322</phone>
    </contact>
    <investigator>
      <last_name>Arkadiy Stolyar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Neurological Associates, PC</name>
      <address>
        <city>Lawrence</city>
        <state>Massachusetts</state>
        <zip>01843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>978-655-7155</phone>
    </contact>
    <investigator>
      <last_name>Andreas P. Schoeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-744-1310</phone>
    </contact>
    <investigator>
      <last_name>David DiBenedetto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>763-302-4162</phone>
    </contact>
    <investigator>
      <last_name>Rajiv Aggarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Mercy Pediatric Clinical Research Unit</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>816-302-3328</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Dilts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-893-8968</phone>
    </contact>
    <investigator>
      <last_name>Donald Johns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ashok K. Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226-0000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-250-2000</phone>
    </contact>
    <investigator>
      <last_name>Jennifer McVige</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>516-325-7001</phone>
    </contact>
    <investigator>
      <last_name>Robert Duarte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health- Division of Pediatric Neurology</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>516-465-5255</phone>
    </contact>
    <investigator>
      <last_name>Ivan Pavkovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-636-4222</phone>
    </contact>
    <investigator>
      <last_name>Marielle Kabbouche-Samaha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-692-6207</phone>
    </contact>
    <investigator>
      <last_name>Catalina Cleves-Bayon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-650-6155</phone>
    </contact>
    <investigator>
      <last_name>Nathan L Bennett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Providence</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David L. Fried</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-867-6906</phone>
    </contact>
    <investigator>
      <last_name>Eric Remster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Neurology Clinical &amp; Diagnostic Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>832-831-7800</phone>
    </contact>
    <investigator>
      <last_name>Monika Ummat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-987-7853</phone>
    </contact>
    <investigator>
      <last_name>Heidi Blume</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanos Aalborg</name>
      <address>
        <city>Gandrup</city>
        <state>North Jutland</state>
        <zip>9362</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>004573708221</phone>
    </contact>
    <investigator>
      <last_name>Helene Rovsing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Universitets Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>004538685131</phone>
    </contact>
    <investigator>
      <last_name>Nanette Mol Debes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Astrid Gendolla</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00492011700350</phone>
    </contact>
    <investigator>
      <last_name>Astrid Gendolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G.B. Pant Institute of Postgraduate Medical Education &amp; Research</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919718599306</phone>
    </contact>
    <investigator>
      <last_name>Debashish Chowdhury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01126594679</phone>
    </contact>
    <investigator>
      <last_name>Sheffali Gulati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0114224000</phone>
    </contact>
    <investigator>
      <last_name>Anshu Rohtagi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Panchshil hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>07927506336</phone>
    </contact>
    <investigator>
      <last_name>Sidharth Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mangala Hospital &amp; Mangala Kidney Foundation</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8242443088</phone>
    </contact>
    <investigator>
      <last_name>Shankara Nellikunja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Getwell Hospital and Research Institute</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>07126632200</phone>
    </contact>
    <investigator>
      <last_name>Prafulla Shembalkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences - Nagpur</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>441108</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>7122352004</phone>
    </contact>
    <investigator>
      <last_name>Meenakshi Girish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospitals Kolkata</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>03323203040</phone>
    </contact>
    <investigator>
      <last_name>Arijit Chattopadhyay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOSD di Neuropsichiatria Infantile</name>
      <address>
        <city>Napoli</city>
        <state>Naples</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>393496675090</phone>
    </contact>
    <investigator>
      <last_name>Marco Carotenuto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00393461076482</phone>
    </contact>
    <investigator>
      <last_name>Licia Grazzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesu</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>00390668592289</phone>
    </contact>
    <investigator>
      <last_name>Massimiliano Valeriani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Roma La Sapienza - Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>003288792966</phone>
    </contact>
    <investigator>
      <last_name>Paola Verdecchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konan Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>658-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shigekazu Kitamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamaguchi Clinic</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8204</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Michio Yamaguchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sendai Headache and Neurology Clinic</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>982-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yasuhiko Matsumori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Headache Clinic</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>151-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kazutaka Shimizu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical Univ. Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Gaku Yamanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umenotsuji Clinic</name>
      <address>
        <city>Kochi</city>
        <zip>780-8011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hiroshi Yamada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tatsuoka Neurology Clinic</name>
      <address>
        <city>Kyoto</city>
        <zip>600-8811</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yoshihisa Tatsuoka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tominaga Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5560017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Takao Takeshima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Federal District</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Juan Carlos Garcia Beristain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Civil De Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hugo Ceja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PanAmerican Clinical Research S.A.de C.V. Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>JA</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3336161585</phone>
    </contact>
    <investigator>
      <last_name>Ixiu del Carmen Cabrales Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Medica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20116</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarug Reyes Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación en Salud</name>
      <address>
        <city>Chihuahua</city>
        <zip>31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>526144372837</phone>
    </contact>
    <investigator>
      <last_name>Avril Molina Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Samuel Sanchez PSC</name>
      <address>
        <city>Caguas</city>
        <zip>00727</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877463136</phone>
    </contact>
    <investigator>
      <last_name>Karen Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7878402580</phone>
    </contact>
    <investigator>
      <last_name>Odette Olivieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Diaz Hernandez</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(787) 523-9808</phone>
    </contact>
    <investigator>
      <last_name>Ileana Fumero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34935565986</phone>
    </contact>
    <investigator>
      <last_name>Roberto Belvis Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34932746606</phone>
    </contact>
    <investigator>
      <last_name>Patricia Pozo Rosich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34955012593</phone>
    </contact>
    <investigator>
      <last_name>M. del Carmen González Oria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34961973910</phone>
    </contact>
    <investigator>
      <last_name>JOSE MIGUEL LAINEZ ANDRES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34983420000</phone>
    </contact>
    <investigator>
      <last_name>Angel Luis Guerrero Peral</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/3ZYuzhkEA0eK8qoWk6AUq2</url>
    <description>A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine</description>
  </link>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>children</keyword>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>headache</keyword>
  <keyword>pediatric migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

